AIAI Holdings' MediGuide Launches Longevity Intelligence, Redefining Personalized Preventive Healthcare
New service combines advanced diagnostics, predictive health intelligence and world-class physician expertise to enable earlier detection and expert resolution
DALLAS, TX / ACCESS Newswire / August 6, 2026 / AIAI Holdings Corporation (NASDAQ:AIAI) ("Ai2" or the "Company"), an AI-enabled diversified holding company utilizing Transformational AI (TAI) to enhance portfolio performance, today announced that its portfolio company, MediGuide, has launched its Longevity Intelligence Service, the latest advancement in its expanding precision healthcare platform.
MediGuide's Longevity Intelligence is a service designed to help individuals better understand their biological health, identify potential health risks earlier and receive personalized clinical guidance through an integrated preventive healthcare solution that combines advanced diagnostics, predictive health intelligence, physician expertise and coordinated care.
"One of Ai2's core investment strategies is partnering with exceptional management teams that leverage technology to expand their market opportunity and create long-term shareholder value," said Todd Furniss, Chief Executive Officer and Co-Founder of AIAI Holdings. "The launch of MediGuide Longevity Intelligence demonstrates that strategy in action. By expanding from a global leader in Medical Second Opinions into precision and preventive healthcare, MediGuide is strengthening its competitive position while addressing one of healthcare's fastest-growing markets."
"The future of healthcare is no longer just treating disease, it's helping people understand their health before disease develops," said Vera Guerreiro, Chief Executive Officer of MediGuide. " MediGuide's Longevity Intelligence reflects that vision by combining advanced diagnostics, physician expertise and personalized health insights to help people make more informed decisions throughout their healthcare journey."
Unlike conventional health assessments that primarily evaluate existing conditions, the MediGuide Longevity Intelligence is designed to provide a comprehensive understanding of an individual's current health status, future health trajectory and personalized opportunities for intervention through four integrated layers of medical intelligence.
Biological Intelligence
Evaluates advanced biomarkers to provide insight into an individual's biological age relative to their chronological age.
Trajectory Intelligence
Analyzes biomarkers, lifestyle factors and family history to identify potential future health risks before symptoms develop.
Intervention Intelligence
Delivers personalized, evidence-based recommendations prioritized and validated through physician specialist review.
Delivery Intelligence
Coordinates ongoing care through MediGuide's global healthcare platform, including Medical Second Opinion and Medical Treatment Abroad services when clinically appropriate.
Together, these capabilities are designed to provide individuals with a more complete understanding of where their health stands today, where it may be heading tomorrow, and the personalized actions that may improve long-term health and quality of life. As the service evolves, Ai2's Transformational AI is expected to help MediGuide convert biomarker, lifestyle and clinical data into explainable risk insights and personalized care-pathway recommendations, while improving case intake, clinical-document review, payer-rule interpretation and global care coordination.
More information can be found here: https://www.mediguide.com/.
About AIAI Holdings Corporation
AIAI Holdings Corporation (Ai2) (NASDAQ:AIAI) is an AI-enabled diversified holding company that acquires and grows companies across multiple industries. We expect to drive revenue and earnings growth throughout our portfolio by applying exclusively licensed Transformational AI to enhance operational efficiency and financial performance.
Ai2 is building a next-generation model for technology-enabled business operations, which is expected to create sustainable value for shareholders through the strategic integration of artificial intelligence across diverse industries.
About MediGuide
MediGuide is a global medical intelligence company dedicated to helping individuals make informed healthcare decisions when they matter most. Founded in 1999, the Company provides Medical Second Opinions, Medical Treatment Abroad, Digital Health, and Preventive Health solutions through an integrated healthcare platform that connects members with world-renowned medical centers and leading specialists around the globe.
Operating across more than 160 countries with a network spanning five continents, MediGuide partners with insurers, employers, financial institutions, and healthcare organizations to deliver expert clinical guidance, personalized care navigation, and innovative digital health services. By combining world-class medical expertise with advanced technology and AI-enabled healthcare solutions, MediGuide empowers patients with greater confidence, improved clinical outcomes, and access to the highest standards of care worldwide. Learn more at MediGuide.
MediGuide is a portfolio company of AIAI Holdings Corporation (NASDAQ:AIAI).
Cautionary Note Regarding Forward Looking Statements
This press release contains "forward-looking statements" or "forward-looking information" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the plans, intentions, beliefs, and current expectations of the Company with respect to future business activities and plans of the Company. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations, intentions, beliefs, plans, objectives, goals, strategies, future events or performance, and underlying assumptions. Forward-looking statements are often identified by the use of words such as "may," "will," "expect," "believe," "anticipate," "intend," "would," "could," "should", "estimate," "plan," "predict," "project," or "continue," or similar expressions, including the negative of these terms or other comparable terminology.
Forward-looking statements are based on the Company's current expectations regarding its strategy, plans, intentions, performance, or future occurrences or results, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of known and unknown risks, uncertainties, and other factors, many of which are outside of the Company's control, that could cause actual results, performance, or achievements to materially differ from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks, uncertainties and other factors include, but are not limited to our lack of operating history, our ability to attract new investments, our failure to manage growth effectively, our acquisition activities may pose risks that could harm our business, and our licensed AI may not perform up to the expected standards, as well as general business and economic conditions, competitive pressures, regulatory changes, technological developments, and other factors identified in the Company's most recent filings with the U.S. Securities and Exchange Commission, including our Registration Statement on Form S-1, which are available for review at www.sec.gov. Furthermore, the Company operates in a competitive environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results.
The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any intention to, and, except as may be required by law, undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which the Company hereafter become aware. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Investor Relations
Matthew Selinger, Senior Partner
Integrous Communications
Email: mselinger@integcom.us
Phone: 415-572-8152
Visit and follow AIAI Holdings Corporation online:
Website: www.aiaiholdings.com
LinkedIn: https://www.linkedin.com/company/aiaiholdings/
X/Twitter: https://x.com/_AiSquared
Instagram: https://www.instagram.com/_aisquared/
Facebook: https://www.facebook.com/aiaiholdings
SOURCE: AIAI Holdings Corporation
View the original press release on ACCESS Newswire